Revenue of USD 1,406.4 million was generated in the global pyrogen test market for 2023, which is expected to grow at a compound annual growth rate of 7.3% over the period from 2024 to 2030 and reach USD 2,284.2 million. This growth of the market can be credited to the increasing acceptance of pyrogen testing within the biopharmaceutical sector.
 |
| To learn more about this report: https://bit.ly/3viQeS0 |
Furthermore, the rising development in the biotechnology and pharmaceutical industries along with the increasing count of new biologics research and introductions is projected to fuel the demand for these testing for making safe and better drugs.
Pyrogen testing is a vital step for each medication and therapeutics to make it safer and more effective. Surge in the count of cancer cases and hereditary illnesses, modified treatments attained benefits in the treatment of these diseases.
Tailored medicine has the benefit that it uses people’s hereditary profiles to aid in decision-making for the prevention, diagnosis, and treatment of illnesses. Therefore, patients and businesses are quickly accepting modified drugs. Furthermore, modified treatment-based methods to clinical and genomic features are becoming more popular among patients with cancer and immunologic sicknesses. Hence, the increasing need for modified drugs is one of the key reasons propelling the demand for pyrogen testing solutions.
In the North American region, the U.S. dominates the industry. This is mainly because of the existence of advanced healthcare infrastructure, augmented concentration on new drug growth, and the presence of key biotechnology and biopharmaceutical companies, like Pfizer Inc. and F. Hoffmann-La Roche AG, in the country.
Furthermore, Canada is also generating substantial revenue for the North American industry. This can be credited to the rising pharmaceutical and biotechnology sector, the rising awareness regarding the safety of medications, and the growing R&D activities in the country.
